We are live on ! Find out more
HS

HighVista Strategies Portfolio holdings

AUM $362M
1-Year Est. Return 230.96%
This Fund
S&P 500
This Quarter Est. Return
+50.91%
1 Year Est. Return
+230.96%
3 Year Est. Return
+518.4%
5 Year Est. Return
+644.94%
10 Year Est. Return
+2,223.31%
AUM
$388M
AUM Growth
-$19.7M
Cap. Flow
-$118M
Cap. Flow %
-30.34%
Top 10 Hldgs %
28.14%
Holding
181
New
33
Increased
26
Reduced
86
Closed
36

Top Buys

Rank Stock Value
1
SLNO
Soleno Therapeutics
SLNO
+$6.38M
2
MAZE
Maze Therapeutics
MAZE
+$5.85M
3
TERN
Terns Pharmaceuticals
TERN
+$4.05M
4
PHVS icon
Pharvaris
PHVS
+$3.91M
5
STOK icon
Stoke Therapeutics
STOK
+$3.47M

Top Sells

Rank Stock Value
1
PRAX icon
Praxis Precision Medicines
PRAX
+$12.9M
2
MRUS
Merus
MRUS
+$12.6M
3
ABVX
Abivax
ABVX
+$12.3M
4
SNDK
Sandisk
SNDK
+$8.63M
5
DBC icon
Invesco DB Commodity Index Tracking Fund
DBC
+$8.61M

Sector Composition

Rank Sector Weight
1 Healthcare 69.79%
2 Technology 6.85%
3 Industrials 5.94%
4 Financials 3.09%
5 Consumer Discretionary 2.49%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
MLYS icon
26
Mineralys Therapeutics
MLYS
$2.41B
$4.52M 1.16%
124,544
-85,285
-41% -$3.42M
PHVS icon
27
Pharvaris
PHVS
$2.43B
$4.51M 1.16%
+162,370
New +$3.91M
TARS icon
28
Tarsus Pharmaceuticals
TARS
$2.97B
$4.39M 1.13%
53,564
+28,710
+116% +$2.14M
EWTX icon
29
Edgewise Therapeutics
EWTX
$4.84B
$4.25M 1.09%
171,137
-36,964
-18% -$742K
OCUL icon
30
Ocular Therapeutix
OCUL
$2.03B
$4.18M 1.08%
344,067
+237,456
+223% +$2.88M
AGIO icon
31
Agios Pharmaceuticals
AGIO
$1.95B
$4.02M 1.04%
147,662
-47,636
-24% -$1.67M
AMZN icon
32
Amazon
AMZN
$3T
$4.02M 1.03%
17,397
-8,996
-34% -$2.06M
APLS
33
DELISTED
Apellis Pharmaceuticals
APLS
$3.79M 0.98%
150,776
+5,047
+3% +$118K
GH icon
34
Guardant Health
GH
$22.4B
$3.75M 0.97%
36,758
-27,825
-43% -$2.49M
STOK icon
35
Stoke Therapeutics
STOK
$2.08B
$3.67M 0.94%
+115,539
New +$3.47M
CMPS
36
Compass Pathways
CMPS
$1.78B
$3.44M 0.89%
+498,933
New +$3.04M
MSFT icon
37
Microsoft
MSFT
$3.76T
$3.16M 0.81%
6,537
-2,921
-31% -$1.46M
LBRX
38
LB Pharmaceuticals
LBRX
$1.31B
$3.12M 0.8%
+140,107
New +$2.45M
PALI icon
39
Palisade Bio
PALI
$365M
$3.06M 0.79%
+1,300,031
New +$2.5M
GHRS icon
40
GH Research
GHRS
$2.03B
$3.05M 0.79%
240,524
-1,370
-0.6% -$18.7K
ARGX icon
41
argenx
ARGX
$54.2B
$3.02M 0.78%
3,588
-480
-12% -$411K
XOMA
42
DELISTED
Xoma
XOMA
$3M 0.77%
112,917
+7,203
+7% +$232K
TDG icon
43
TransDigm Group
TDG
$67.6B
$2.89M 0.74%
+2,175
New +$2.85M
RNAM
44
DELISTED
Avidity Biosciences
RNAM
$2.89M 0.74%
40,020
-25,560
-39% -$1.65M
AMLX icon
45
Amylyx Pharmaceuticals
AMLX
$2.53B
$2.88M 0.74%
+238,812
New +$3.24M
BBOT
46
BridgeBio Oncology
BBOT
$743M
$2.87M 0.74%
+229,263
New +$2.78M
NVDA icon
47
NVIDIA
NVDA
$5.27T
$2.65M 0.68%
14,220
+820
+6% +$153K
CRM icon
48
Salesforce
CRM
$162B
$2.28M 0.59%
8,613
-4,272
-33% -$1.06M
V icon
49
Visa
V
$675B
$2.21M 0.57%
6,291
-1,570
-20% -$535K
SEPN
50
Septerna Inc
SEPN
$1.75B
$2.19M 0.56%
+78,682
New +$1.88M
1
2
3 4 5

Similar funds

SIAG
Safeguard Investment Advisory Group Corona, California $362M AUM 20.96% 1-Year Est. Return
MS
Millington Securities Red Bank, New Jersey $362M AUM
WI
WBI Investments Red Bank, New Jersey $362M AUM 23.75% 1-Year Est. Return
WTFG
Wood Tarver Financial Group Boise, Idaho $362M AUM 14.75% 1-Year Est. Return
VIA
Virtus Investment Advisers Hartford, Connecticut $363M AUM 34.89% 1-Year Est. Return
A6
Anchor @ 65 Singapore $362M AUM 20.02% 1-Year Est. Return
PI
Pennant Investors Summit, New Jersey $361M AUM 134.26% 1-Year Est. Return
ACM
Anfield Capital Management Irvine, California $363M AUM 24.08% 1-Year Est. Return

HighVista Strategies's Q4 2025 Portfolio in Review

As of Q4 2025, HighVista Strategies held 181 positions worth $388M, down 4.8% from $408M the previous quarter. Its ten largest holdings account for 28% of the portfolio.

HighVista Strategies withdrew a net $118M in Q4 2025, closing 36 positions and reducing 86 holdings. Its most notable exit was Merus, an estimated $12.6M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 70% of assets, up from 59% a quarter earlier, followed by Technology and Industrials.

Against the trend, HighVista Strategies opened a new position in Maze Therapeutics worth $7.06M.

  • HighVista Strategies's largest Q4 2025 buy was Maze Therapeutics: 170,353 shares worth $7.06M.
  • HighVista Strategies added most to Soleno Therapeutics in Q4 2025, an estimated $6.38M increase.
  • HighVista Strategies's biggest Q4 2025 reduction was Praxis Precision Medicines, cutting an estimated $12.9M.
  • HighVista Strategies fully exited Merus in Q4 2025, selling an estimated $12.6M.
  • HighVista Strategies's ten largest holdings make up 28% of its $388M portfolio in Q4 2025.
  • HighVista Strategies opened 33 new positions and closed 36 in Q4 2025.
  • HighVista Strategies's portfolio value fell 4.8% quarter-over-quarter to $388M.

Based on HighVista Strategies's 13F filing for Q4 2025, filed 17 Feb 2026.